GlassScriptPhysician profile
Helen Phan Tran
NPI 1376091264
$3,410.07
in general payments reported to CMS, 2019-2025
15 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.24 · 2022: $121 · 2023: $392 · 2024: $1,451 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $952.27 | 2023-2025 | Rocklatan, Precision 1, Dailies Total1 |
| Bausch & Lomb Americas INC. | $851.59 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $471.78 | 2023-2025 | Cequa |
| Oyster Point Pharma, INC. | $306.86 | 2023-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $195.38 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $180.66 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $121.36 | 2022 | |
| Ani Pharmaceuticals, INC. | $84.67 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Abbvie INC. | $70.55 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $42.10 | 2025 | |
| Thea Pharma INC. | $42.08 | 2024-2025 | Iyuzeh |
| Amgen INC. | $28.12 | 2024 | Tepezza |
| Novo Nordisk INC | $25.00 | 2023 | Ozempic |
| Rayner Intraocular Lenses Limited | $20.41 | 2025 | Omidria |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.